The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending booster shots.

Significant delays in core FDA functions — such as approving amendments to clinical trials and guiding companies through ...

RSV vaccines could get broader CDC backing for adults aged 50-59 at risk after an endorsement from an agency's expert panel. Read more here.

A complaint against GSK accusing it of a major breach of the pharma industry's code of practice on prescribing information has been upheld after a review by the Prescription Medicines Code of Practice ...

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

If the tariff-loving Trump goes ahead with his plans, it will hit AstraZeneca - the most valuable company on the UK stock ...

Guidelines from the Advisory Committee on Immunization Practices help physicians decide what vaccines to recommend to ...